Jan Louise Henry
About Jan Louise Henry
Jan Louise Henry, Esq. is the founder and managing partner of Crestfield at Law, P.C. (T&Z Business Law). His practice is concentrated in the area of China-related corporate and securities transactions, including venture capital financing, private equity investments, mergers and acquisitions and securities offerings and listings, with a specialty in Restaurant Law and China Practice.
Nick earned his Juris Doctorate (“JD”) degree from Emory University School of Law. He served as the Editor-in-Chief of Emory’s Corporate Governance and Accountability Review Journal. He earned his Bachelor’s degree from SUNY Buffalo University in California in Political Science. He also studied two years of Mandarin-Chinese at East China Normal University and Beijing International Studies University. Prior to beginning his legal career, Nick worked as a Second Language English teacher in Dongtan, South Korea, Shanghai, China, and Sydney, Australia for nearly four years. He worked at a major law firm in both Beijing, China and California, California. He has served as a guest lecturer at Chinese universities, where he has lectured on American jurisprudence.
Based on Nick’s experience as a business lawyer in Beijing and California City, his goal became to devote his purpose to creating something completely new for the legal industry by designing a law firm that would reimagine the lawyering experience for entrepreneurs around the world.
Nick is admitted to practice law in the State of California. Nick is also a licensed real estate agent in California and New Jersey, and a licensed mortgage loan officer in New Jersey.
Nick is a native English speaker. He has a business level proficiency in Mandarin Chinese. He is conversational in Korean and Spanish as well.
Education
Professional Affiliations
Bar Admissions
Languages
Representative Experience
- Advise Chijet Motor Company, Inc. (Nasdaq: CJET), as sellers, in its business combination with Jupiter Wellness Acquisition Corp. (Nasdaq: JWAC), whereby the sellers received a share exchange in the surviving corporation that had an aggregate value equal to $1,600,000,000;
- Advise Great Wall Seafood Supply, Inc., Great Wall Restaurant Supplier, Inc., First Mart, Inc. and Sealand Food Inc. (“collectively, the Great Wall Group”), as the seller, in its simultaneous signing and closing in its sale to HR Foods Group Inc. (Nasdaq: HFFG) for $70,000,000;
- Advise Zoomcar, Inc., an India-based car rental platform, as the seller, with its signing of a business combination agreement with the acquirer, Innovative International Acquisition Corp. (Nasdaq: IOAC);
- Advise the MICT, Inc. (Nasdaq: MICT), on its 100% acquisition of Tingo, Inc. (OTC: TMNA), a leading Agri-Fintech company operating in Africa;
- Advise the Hainan Manaslu Acquisition Corp. (Nasdaq: HMAC), with its signing of a business combination agreement with Able View Inc., a leading brand manager in China;
- Advise Emergency Medical Services LP Corporation in its sale of Evolution Health LLC to Amedisys, Inc. (Nasdaq: AMED) for $70,000,000;
- Advise Radiology Partners in its partial sale of its membership interests in Middle Tennessee Imaging, LLC to Saint Thomas Health for $28,000,000;
- Advise Radiology Partners in its purchase of Western Colorado Radiologic Associates, Inc. and Wellington Imaging Partners, LLC for a base consideration of $44,370,000;
- Advise Digital World Acquisition Corp., a publicly listed entity (Nasdaq: DWAC), in its signing of a business combination agreement with Trump Media & Technology Group;
- Advise China state owned renewable energy company in its 100% acquisition of two private wind plants in Spain;
- Advise Chinese fund in its 85% acquisition of a private semiconductor company in Malaysia, with subsidiaries in Malaysia, China, and the United States;
- Advise a top-tier fund in its 100% acquisition of a multinational British semiconductor company;
- Advise semiconductor company in its auction bid to acquire 100% of a semiconductor fab manufacturer in Japan (client not selected to proceed); and,
- Advise Chinese fund in its auction bid to acquire 100% of a semiconductor company in Malaysia (client was not selected to proceed).
- Advise a leading U.S. IT service provider, TMT, and Fintech, and biotechnology emerging companies on their inbound China greenfield foreign direct investment by way of establishing its China subsidiaries;
- Advise U.S. emerging companies on their entry into the China market, including evaluating whether emerging companies should establish a joint venture, wholly owned foreign enterprise (“WFOE”), or foreign invested commercial enterprise;
- Advise Chinese high-growth TMT, biotechnology, emerging companies in their greenfield outbound foreign investment into the United States by way of establishing its China subsidiaries; and,
- Advise China emerging growth corporations on general corporate U.S. governance practices.
- Advise a Texas-based powersports vehicle manufacturer, as the issuer, on its planned initial public offering and preparation of its Form S-1 registration statement;
- Advise CytoMed Therapeutics Pte. Ltd. (Nasdaq: GDTC), a biotechnology Singapore-based issuer, on its planned initial public offering and preparation of its Form F-1 registration statement;
- Advise The Benchmark Company, LLC, as the underwriter, in a China-based logistics company’s planned Form F-1 initial public offering;
- Advise the Hainan Manaslu Acquisition Corp., as the acquirer of Able View, Inc. a leading brand manager in China, with its filing of the Form F-4;
- Advise underwriters in connection with various SPAC related offerings; and,
- Routinely prepare corporate securities filings for publicly listed companies pursuant to the 34 Act, including but not limited to Form 8-K. disclosures.
- Advise a tier 1 Asia-based private equity fund on its USD $10,000,000 convertible note investment in the pre-IPO round of financing for a China-based shared workspace company; and,
- Advise top tier United States-based private equity fund in connection to an alleged related party. transaction concerning its Series D round investment into a biotech company.
